BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 31003902)

  • 1. Immunotherapy of gynecological cancers.
    Matanes E; Gotlieb WH
    Best Pract Res Clin Obstet Gynaecol; 2019 Oct; 60():97-110. PubMed ID: 31003902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immuno-oncology for Gynecologic Malignancies.
    How J; Patel A; Jazaeri A
    Adv Exp Med Biol; 2020; 1244():149-182. PubMed ID: 32301014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.
    Zamarin D; Jazaeri AA
    Gynecol Oncol; 2016 Apr; 141(1):86-94. PubMed ID: 27016233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in gynecological cancers: where are we?
    Polastro L; Closset C; Kerger J
    Curr Opin Oncol; 2020 Sep; 32(5):459-470. PubMed ID: 32675594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers.
    Liu YL; Zamarin D
    Curr Oncol Rep; 2018 Nov; 20(12):94. PubMed ID: 30421009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
    Gadducci A; Guerrieri ME
    Anticancer Res; 2017 Nov; 37(11):5955-5965. PubMed ID: 29061774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of cancer immunotherapy for gynecologic malignancies.
    Nishio H; Iwata T; Aoki D
    Jpn J Clin Oncol; 2021 Feb; 51(2):167-172. PubMed ID: 33244581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immune checkpoint (PD-1 and CTIA-4) signal inhibitors for gynecologic oncology; up to date].
    Hamanishi J; Mandai M; Konishi I
    Nihon Rinsho; 2017 Feb; 75(2):234-244. PubMed ID: 30562858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.
    Menderes G; Hicks C; Black JD; Schwab CL; Santin AD
    Expert Opin Biol Ther; 2016 Aug; 16(8):989-1004. PubMed ID: 27070175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in Gynecologic Cancers: Are We There Yet?
    Pakish JB; Jazaeri AA
    Curr Treat Options Oncol; 2017 Aug; 18(10):59. PubMed ID: 28840453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?
    Taha T; Reiss A; Amit A; Perets R
    BioDrugs; 2020 Dec; 34(6):749-762. PubMed ID: 33141420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-Oncology for Gynecologic Malignancies.
    How JA; Patel A; Jazaeri AA
    Adv Exp Med Biol; 2021; 1342():193-232. PubMed ID: 34972966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
    Lee L; Matulonis U
    Gynecol Oncol; 2019 Jul; 154(1):236-245. PubMed ID: 30995960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers.
    Di Tucci C; Schiavi MC; Faiano P; D'Oria O; Prata G; Sciuga V; Giannini A; Palaia I; Muzii L; Benedetti Panici P
    Crit Rev Oncol Hematol; 2018 Aug; 128():30-42. PubMed ID: 29958629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.
    Jazaeri A; Coleman RL; Sood AK; Frumovitz MM; Soliman PT; Shafer A; Cutrera JJ; Klinger M; Sharafi SE; Johnson CAL; Villanueva VF; Hinchcliff EM; Dickens A; Cain KE; Anderson JE; Lu KH; Westin SN
    Gynecol Oncol; 2018 Nov; 151(2):374-380. PubMed ID: 30213435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors.
    Grywalska E; Sobstyl M; Putowski L; Roliński J
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.
    Coosemans A; Vergote I; Van Gool SW
    Expert Rev Clin Immunol; 2014 Jun; 10(6):705-11. PubMed ID: 24784346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell target antigens across major gynecologic cancers.
    Rodriguez-Garcia A; Minutolo NG; Robinson JM; Powell DJ
    Gynecol Oncol; 2017 Jun; 145(3):426-435. PubMed ID: 28377094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors.
    Curigliano G
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):253-258. PubMed ID: 29775688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.